- Conditions
- Renal Dysfunction, Acute Renal Failure, Mortality
- Interventions
- URODILATIN (ULARITIDE, ATRIAL NATRIURETIC PEPTIDE), MANNITOL
- Drug
- Lead sponsor
- Rocky Mountain Cancer Centers
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 1
- States / cities
- Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 2, 2008 · Synced May 21, 2026, 10:10 PM EDT